<DOC>
	<DOCNO>NCT02607410</DOCNO>
	<brief_summary>To compare short long term effect inhibitor DPP-IV enzyme , sitagliptin , bedtime NPH insulin patient T2D inadequately control sulphonylurea plus biguanide : effect beta cell function metabolic profile .</brief_summary>
	<brief_title>Sitagliptin ( DPP-4 Inhibitor ) NPH Insulin Patients With T2D</brief_title>
	<detailed_description>Glucose control fundamental treatment type 2 diabetes ( DM2 ) . Studies suggest drug boost level glucagon-like peptide ( GLP-1 ) improve glycemic control long-term beneficial effect function pancreatic beta cell . Objective : To compare short long term effect sitagliptin ( inhibits DPP-IV enzyme , increase level GLP-1 ) bedtime NPH insulin patient T2D inadequately control sulphonylurea plus biguanide . Effects beta cell function metabolic profile analyze . Methods : 40 patient DM2 , HbA1c 6.6 10 % , use metformin glibenclamide randomize addition sitagliptin ( Sitagliptin Group ) bedtime NPH insulin ( NPH Group ) . Measurements HbA1c , metabolic hormonal profile fast post-meal ( every 30 minute 4 hour ) evaluate 6 month ( short term ) 12 month ( long term ) add sitagliptin NPH insulin .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Inclusion Criteria outpatient T2D inadequately control metformin plus glyburide HbA1c level 6.6 10 % body mass index &lt; 35 kg/m2 Exclusion Criteria heart failure respiratory failure uncontrolled hypertension impair hepatic function impair reanl function endocrine disorder gastrointestinal disorder malignancy alcohol abuse previous use insulin previou use base incretin therapy type 1 diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>NPH insulin</keyword>
	<keyword>GLP-1</keyword>
</DOC>